Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Earnings

Cannara Reports Q2 Fiscal 2026 Results with Continued Profitability, Strong Operating Cash Flow and #1 Retail Market Share in Quebec

Cannara Biotech Confirms Profitability Amidst Revenue Growth Deceleration

By The Northwire Desk — AI Analysis Apr 14, 2026 · 07:00 LOVE · 2.05 Cannara Biotech Inc.
Executive Summary
  • Event: Cannara Biotech reported Q2 Fiscal 2026 financial results on April 14, 2026.
  • Revenue: Total net revenues of $27.2 million (up 2% YoY); Gross cannabis revenues of $37.8 million (up 3% YoY). This represents a significant slowdown compared to Q1 Fiscal 2026, which saw 20% YoY revenue growth.
  • Profitability: Net income of $1.7 million ($0.02 per share), down from $3.3 million in Q2 2025. Adjusted EBITDA was $6.0 million, down from $7.1 million YoY.
  • Cash Flow: Operating cash flow improved significantly to $2.9 million compared to -$2.6 million in the prior year period.
  • Market Share: Achieved #1 retail market share position in Quebec (14.3%) and increased national retail market share to 4.4%.
  • Capital: Completed a non-brokered private placement with Phoenician Capital LLC for $6.3 million (3,000,000 shares at $2.10/share), announced previously in February 2026.
  • Operations: Capital expenditures were $3.2 million, primarily for the Valleyfield Facility construction project.
Material Impact
  • Positive Aspects: The company has successfully transitioned to positive operating cash flow ($2.9M vs -$2.6M), which is a critical milestone for liquidity and reduces immediate dilution risk. Maintaining profitability (Net Income $1.7M) in a challenging cannabis market validates the business model. Market share gains in Quebec (#1 position) provide a defensive moat in their home province.
  • Negative Aspects: Revenue growth has decelerated sharply from 20% YoY in Q1 to just 2% YoY in Q2. Adjusted EBITDA declined year-over-year ($7.1M to $6.0M), suggesting margin pressure or increased operational costs relative to sales. The private placement price of $2.10 is close to the current trading price, indicating limited upside from this capital raise alone.
  • Conclusion: The news confirms execution on profitability and cash flow but signals a maturation phase where high growth rates are difficult to sustain. It does not materially alter the investment thesis established in FY25 and Q1 2026, hence it is Routine - Positive rather than Material - Positive.
LOVE · Price
Company Overview
  • Overview: Cannara Biotech is a vertically integrated cannabis company focused on premium consumer brands (Tribal, Nugz, Orchid CBD). They operate cultivation and processing facilities in Quebec.
  • Flagship Project: The Valleyfield Facility is the core growth driver. It includes a mega-production facility with 24 grow zones. Phase 1 completion was targeted for FY2026. Expansion plans include activating three additional grow zones for FY2027.
  • Development Status: As of Q2 2026, construction is progressing, and half of the 24-zone capacity was active in previous reports (Q1 2026).
Read the original news release →

More from Cannara Biotech Inc.

May 06, 2026 · 08:00

Cannara Consolidates Quebec Operations

M&A / Property Apr 07, 2026 · 07:00

Cannara Biotech Inc.

Earnings Feb 26, 2026 · 08:00

Cannara Announces Graduation to the Toronto Stock Exchange

Regulatory Feb 04, 2026 · 17:47

Cannara Biotech closes $6.3-million private placement

Financings Feb 04, 2026 · 08:00

Cannara Announces Strategic C$6.3 Million Non-Brokered Private Placement Priced at C$2.10 per Common Share

Financings Jan 28, 2026 · 08:00

Cannara Announces Conditional Approval to List on the Toronto Stock Exchange

Regulatory